I2I May 18, 2015 — How to Talk to Industry
The Office of Technology Commercialization
Invention to Innovation (I2I)
“How to Talk to Industry”
Executive Director, Transactions External Research & Development
Date and Time: Monday, May 18, 2015, 12-1:30pm
Location: Leavey Program Room at the Leavey Center (across from bookstore)
This presentation will provide insight into how industry identifies, reviews and finalizes collaborations with academicians. Key considerations to keep in mind when talking to industry will be discussed.
Lunch will be provided; space is limited.
PLEASE RSVP by May 14, 2015 to Azra Chughtai at acf43 at georgetown dot edu or 202-687-7424
Faculty, entrepreneurs, fellows, students and research administrators should attend.
About Bethany Mancilla:
Bethany Mancilla is Executive Director, Transactions for Amgen. Since joining Amgen in April 2012, Ms. Mancilla led the execution of a multi-product cardiovascular collaboration with Servier that included US rights to ivabradine for heart failure. She also completed the world-wide out-license of motesanib, a phase 3 program in oncology to Japanese partner Takeda. In 2015 she was selected as a top woman at Amgen who has helped build the company’s history and is impacting the world of science, technology, and business.
Prior to joining Amgen, Ms. Mancilla served as the Vice President of Business Development and Alliance Management for Micromet from April 2010 to March 2012. During this time she negotiated the one billion dollar, multi-target BiTE® antibody collaboration with Amgen which led to the acquisition of Micromet by Amgen.
From February 2008 until March 2010, Bethany was the Vice President of Business Development and Licensing for PharmAthene a developer of biologics and vaccines for the biodefense and emerging infectious disease markets. Prior to joining PharmAthene, Bethany was the head of Business Development for Gene Logic. During her ten year span with the company she spear-headed several multi-million dollar partnerships with major pharmaceutical companies including Pfizer, Roche, Wyeth, Lilly, Organon, Solvay and Abbott.
Ms. Mancilla began her career as the Director of Business Development for BCM Technologies, the for-profit subsidiary of Baylor College of Medicine, where she was involved in the creation and financing of four start-up biotechnology companies. Ms. Mancilla received an M.B.A. from the University of Houston and a B.A. from the University of Colorado.